Haemophilia A and haemophilia B are the commonest form of haemophilia encountered and they result from a defect in Factor VIII and Factor IX gene respectively. This hinders the process of haemostasis and predisposing haemophiliacs to spontaneous or post traumatic bleeding. We wanted to study the clinico-haematological profile of patients with haemophilia.
B A C K G R O U N D
The X-linked recessive inherited coagulation disorders, haemophilia A (Factor VIII deficiency) and haemophilia B (f actor IX deficiency) are the commonest forms of haemophilia. 1, 2 Incidence of haemophilia A is 1 per 5,000 male birth and haemophilia B is 1 per 25,000 male birth. Deficiency of associated factors hamper the process of haemostasis and predisposes haemophiliacs to spontaneous or post traumatic bleeding. Factor deficient individuals have severe, moderate and mild forms of disease, defined by plasma factor levels of <1%, 2-5%, and 6 -40% respectively. 3 It is a sex-linked recessive disease and gene is located on Xq28. Point mutations of the gene are the most prevalent type of genetic defect seen in 90-95% of cases. Males are the sufferer and females are the carriers of this disease. Rare female homozygous cases are encountered. 4 Haemarthrosis is the most common, as well as most physically, psychologically and economically exhausting manifestation of haemophilia. CNS bleeding is the most serious complication of haemophilia which may occur following a trauma or spontaneously. Immediate factor replacement is a must in this case. 5 Activated partial thromboplastin time (APTT) is usually prolonged in patients with haemophilia (PwH). Factor VIII and factor IX assay are simple techniques, used for typing of severity of haemophilia and is done by two stage method, one stage method as well as micro-method. The one stage technique is used widely as it is simple to perform. 6 Bleeding episodes in haemophiliacs are treated with factor replacement therapy. The approximate least desired factor level required to control bleeding episodes is 30% (0.3 units/ml), 50 % (0.5 units/mi) and 80%-100% (0.8-1 unit/ml) in case of mild bleeding, major bleeding and major surgery respectively. Units of factor VIII to be administered are "required rise in % × weight in kg/2" and units of factor IX to be administered are "required rise in % × weight in kg". 7 In developing nations including India, where haemophilia patients have limited access to prophylaxis and treatment, there is widespread suffering and from recurrent and prolonged joint bleeds. Morbidity from joint impairment increases markedly with advancement of age. Beside this, frequent use of blood and blood products as a cheaper substitute of factor concentrate increase the risk of acquiring transfusion transmitted infections in haemophiliacs. 8 The world federation of haemophilia estimates that there are more than 4, 00, 000 individuals worldwide suffering from haemophilia. 80% of the haemophiliacs are in developing countries. In spite of this, in most of the developing countries, a very small amount of resources is spent on this disease. Under such circumstances, data collection for haemophilia remains very low priority. Scarcity of data in the developing countries makes it very difficult to represent the accurate situation regarding the epidemiology, clinical profile and management of these patients. Present study is designed for assessment of the clinical profile of haemophilia patients in central India and which type of clinical presentation must undergo coagulation profile testing to detect cases of haemophilia at the earliest to decrease morbidity and the mortality. Which can be helpful for the policy makers to improve services to detect and treat these patients. [9] [10] 
ME T H O D S
This hospital based observational study was performed on all the patients (100) diagnosed as haemophilia referred to Hamidia Hospital from 1 st March 2017 to 30th June 2018. Sample size was taken based on the convenience of the study. Patients with other bleeding disorders and those were on medication which can alter coagulation profile were excluded from the study. After taking written consent, all patients were subjected for clinical workup consist of a thorough history including relevant family history, general as well as systemic examination & protocol wised laboratory tests were done. Diagnosis of haemophilia was made on the basis of relevant history, physical examination and laboratory investigations such as bleeding time (BT), Prothrombin time (PT), Activated Partial Thromboplastin Time (APTT), correction studies and whenever possible, specific coagulation factor assay. Beside of this, other haematological investigations like complete blood counts including peripheral blood smear were also carried out to see blood cell morphology, platelet count and morphology. The study was approved by the Ethical Committee.
Statistical Analysis
Descriptive analysis of qualitative variables was expressed in frequency and percentages. Statistical average was done by mean value and dispersion was measured by standard deviation. was positive in 40 -70% of cases. These results are in accordance with other studies. 20, 21 In present study, in 52% patients bleeding starts spontaneously while in 48% patients bleeding starts following major or minor trauma. Similar results are seen in study done by R K Nigam 14 et al (Spontaneous bleed -57%, traumatic bleed-33%). While in study done by Shamoon 22 et al percentage of spontaneous and traumatic bleeding in patients was 32% and 68% respectively. Low percentage of patients with spontaneous bleeding can be explained as many mild cases remain undiagnosed, and many others with severe diseases die early due to inadequate management. This is unlike the situation in the west where prophylactic replacement therapy turns young haemophiliacs to live almost normal life.
R E S U L T S
In severe haemophiliac patients, bleeding starts spontaneously and have prolong bleeding episode while in moderate haemophiliac patients, bleeding usually starts after minor or major trauma. In Mild haemophiliac patients, bleeding starts after major trauma. Most common clinical presentation in present study is haemarthrosis (72%). Haemarthrosis as most common clinical manifestation is also seen in study done by Karim et al 12 13 Parthiban et al, 16 Raina et al. 23, [25] [26] [27] [28] In study done by R.K.Nigam 14 et al, percentage of mild, moderate and severe was 32.38%, 36.22% and 31.4% respectively. The difference in percentage of mild, moderate and severe cases between present study and in study done by R. K. Nigam et al 14 appears due to difference in study design. In study done by R. K. Nigam et al 14 all registered patients of haemophilia were studied which resulted in larger sample size and larger spectrum of cases. However present study was observational study where only the patients reporting during the study period were included. Patients with severe haemophilia reports frequently than patients with moderate and mild haemophilia.
C O N C L U S I O N S
Haemophiliacs are distributed worldwide and have heterogeneous presentation depending upon disease severity. Frequency and persistence of blood loss associated even with minimal trauma, especially in the presence of haemarthrosis, bruise and haematoma either spontaneous or traumatic in an otherwise normal child should alert the physician to investigate for haemophilia even in the absence of family history. Knowledge of the spectrum of presentation of haemophilia in the population helps in early diagnosis and management planning. Early recognition is important to establish correct treatment and to avoid unnecessary investigation. Most centers in developing countries including India do not have facility for factor concentration estimation; but clinically, we can assess severity of haemophilia with age of first bleed, type of bleed (like ICH) which should always be considered as severe, for treatment purposes. Factor replacement is the only treatment for haemophilia, ideally recombinant one that too preferably prophylactic. The specialty of transfusion medicine can be a core part of haemophilia care as it provides the laboratory services in the form of haemostasis, lab & serology testing, testing for inhibitors, factor concentrates & blood component support. Thus in future, we can treat PWH (Persons with Haemophilia) without pain & disability by promoting regular availability of factor concentrate, prophylactic factor replacement, establishing comprehensive care center, regular training of medical and paramedical staff, and positive public awareness and a good haemostasis laboratory.
